When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
XLRN - Acceleron bails on ACE-083 after unsuccessful mid-stage study
Acceleron Pharma Inc.
Acceleron Pharma (NASDAQ:XLRN) has decided to terminate development of ACE-083 after a Phase 2 study in patients with Charcot-Marie-Tooth disease, a group of inherited disorders that cause nerve damage, failed to demonstrate functional improvement despite meeting the primary endpoint of a statistically significant increase in mean total muscle volume.
More news on: Acceleron Pharma Inc., Healthcare stocks news,